Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
Milestone Pharmaceuticals (Nasdaq: MIST) will present a poster at the American Heart Association Scientific Sessions 2025 in New Orleans on November 10, 2025. The poster reports combined data on the efficacy, safety, and test-dose tolerability of self-administered etripamil for acute paroxysmal supraventricular tachycardia (PSVT) across multiple clinical trials.
The presentation is by James Ip, M.D. and is scheduled for Monday, November 10, 2025, 10:30–11:30 AM CST. The data describe patient-administered use of etripamil focusing on acute PSVT episodes.
Milestone Pharmaceuticals (Nasdaq: MIST) presenterà un poster alle American Heart Association Scientific Sessions 2025 a New Orleans il 10 novembre 2025. Il poster riporta dati combinati sull'efficacia, sicurezza e tollerabilità della dose di test di etripamil auto somministrato per la tachiaritmia parossistica sopraventricolare acuta (PSVT) attraverso diversi studi clinici.
La presentazione è di James Ip, M.D. e è prevista per lunedì 10 novembre 2025, 10:30–11:30 CST. I dati descrivono l'uso auto-somministrato di etripamil concentrandosi sugli episodi acuti di PSVT.
Milestone Pharmaceuticals (Nasdaq: MIST) presentará un póster en las Scientific Sessions 2025 de la American Heart Association en Nueva Orleans el 10 de noviembre de 2025. El póster reporta datos combinados sobre la eficacia, seguridad y tolerabilidad de la dosis de prueba de etripamil autoadministrado para taquicardia supraventricular paroxística aguda (PSVT) a lo largo de varios ensayos clínicos.
La presentación es de James Ip, M.D. y está programada para el lunes, 10 de noviembre de 2025, 10:30–11:30 AM CST. Los datos describen el uso autoadministrado de etripamil, centrándose en episodios agudos de PSVT.
Milestone Pharmaceuticals (Nasdaq: MIST) 은 뉴올리언스에서 2025년 American Heart Association Scientific Sessions에 포스터를 발표합니다. 발표일은 2025년 11월 10일이며, 포스터는 여러 임상시험에 걸친 자가 투여 에트리파밀의 효능, 안전성 및 시험 용량 내약성에 대한 데이터를 보고합니다.
발표자는 James Ip, M.D.이며 일정은 2025년 11월 10일 월요일, CST 10:30–11:30입니다. 데이터는 급성 PSVT 에피소드를 중심으로 환자 자가 투여 에트리파밀의 사용을 설명합니다.
Milestone Pharmaceuticals (Nasdaq: MIST) présenteront un poster lors des Scientific Sessions 2025 de l'American Heart Association à La Nouvelle-Orléans le 10 novembre 2025. Le poster rapporte des données combinées sur l'efficacité, la securité et la tolérabilité de la dose de test d'étripamil auto-administré pour la tachycardie ventriculaire supraventriculaire paroxystique aigue (PSVT) au travers de plusieurs essais cliniques.
La présentation est effectuée par James Ip, M.D. et est prévue pour le lundi 10 novembre 2025, 10h30–11h30 CST. Les données décrivent l'usage auto-administré de l'étripamil en se concentrant sur les séquences aiguës de PSVT.
Milestone Pharmaceuticals (Nasdaq: MIST) wird auf den Scientific Sessions 2025 der American Heart Association in New Orleans am 10. November 2025 ein Poster vorstellen. Das Poster berichtet über zusammengestellte Daten zur Wirksamkeit, Sicherheit und Testdosen-Toleranz von selbst verabreichtem Etripamil bei akuter paroxysmaler supraventrikulärer Tachykardie (PSVT) über mehrere klinische Studien.
Die Präsentation erfolgt durch James Ip, M.D. und ist vorgesehen für Montag, 10. November 2025, 10:30–11:30 Uhr CST. Die Daten beschreiben die patientenverabreichte Anwendung von Etripamil mit Fokus auf akute PSVT-Episoden.
ستعرض Milestone Pharmaceuticals (الرمز في ناسداك: MIST) ملصقاً في جلسات الجمعية الأمريكية للقلب Scientific Sessions 2025 في نيو أورلينز في 10 نوفمبر 2025. يُبيِّن الملصق بيانات مجمعة عن الفعالية والسلامة و tolerability جرعة الاختبار من etripamil المَدار ذاتياً لعلاج تسرع القلب فوق البطيني النَوبِي الحاد (PSVT) على مدى عدة تجارب سريرية.
العرض مقدّم من James Ip, M.D. ومن المُقرر أن يكون في الاثنين، 10 نوفمبر 2025، 10:30–11:30 صباحاً بتوقيت CST. تُصف البيانات استخدام etripamil المَدَار عن بُعد مع تركيز على نوبات PSVT الحادة.
Milestone Pharmaceuticals (Nasdaq: MIST) 将在 美国心脏协会科学会议 2025 的新奥尔良场地于 2025 年 11 月 10 日 提交一份海报。该海报汇总了自我给药的 etripamil 用于急性发作性室上性心动过速（PSVT）的疗效、安全性和试剂量耐受性在多项临床试验中的数据。
由 James Ip, M.D. 主讲，时间定在 2025 年 11 月 10 日，星期一，CST 10:30–11:30。数据描述了患者自我给药的 etripamil 使用，聚焦于急性 PSVT 发作。
- None.
- None.
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a poster presentation at the American Heart Association Scientific Sessions 2025, to be held November 7-10th in New Orleans, Louisiana. Data to be presented describe the efficacy, safety, and tolerability of self-administered etripamil by patients with episodes of paroxysmal supraventricular tachycardia.
AHA 2025 Presentation Details:
| Poster Presentation Title: | Combined Efficacy, Safety, and Test Dose Tolerability of Etripamil for Acute Paroxysmal Supraventricular Tachycardia (PSVT) Across Multiple Clinical Trials |
| Presenter: | James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital |
| Date and time: | Monday, November 10, 2025, 10:30 – 11:30 AM CST |
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.
Investor Relations
Kevin Gardner, kgardner@lifesciadvisors.com
FAQ
When will Milestone (MIST) present etripamil data at AHA 2025?
What topic will Milestone's AHA 2025 poster on MIST cover?
Who is presenting Milestone's etripamil poster at AHA 2025?
Where and when is the American Heart Association Scientific Sessions 2025 event?
What patient population is described in Milestone's AHA 2025 poster for MIST?
